Friday, October 30, 2009

Influence of N-acetyl-ß-D-glucosaminidase (NAG) excretion on renal and non-renal disease states –A literature review


Dr. Ishrat Ali Siddiqui , Prof; John Feely
Trinity Centre for Research and  Health Sciences
St. James’s Hospital , Dublin 8



In this review, I will give a brief background into the lysosomal glycosidase, N-acetyl-ß-D-glucosaminidase (NAG). Next, I will list out both non-renal and renal conditions that are associated with higher urinary and serum NAG activities. In my third section, I will discuss in detail those common disease states that have an established evidence of an association with higher NAG activity. The fourth section highlights the most plausible biological mechanism underlying such a phenomenon. Finally, I will summarise and conclude my review in the fifth section. Each of the disease conditions discussed in section three will begin with the standard definition of such conditions, before discussing appropriate literature. Detailed bibliographic references are provided in the end of this review.

1.         What is NAG?
N-acetyl-ß-D-glucosaminidase (NAG) is a lysosomal glycosidase found in high concentrations in renal proximal tubules. It is one of the lysosomal enzymes that are widely distributed in human tissues. It is released into serum, urine, and plasma by breakdown of cells or exocytosis. This process occurs due to the very high molecular weight (130000 to 140000) of NAG, and is therefore not normally filtered at the glomerulus. Low levels of NAG are only found in normal urine as a result of normal exocytosis and pinocytotic activity of epithelial cells.

NAG has been shown to be a sensitive marker of early renal tubular injury. A consistent elevation of urinary NAG is always associated with progressive renal damage. NAG can be assayed easily by the help of colorimetric method.

2.         Non-renal and renal causes of urinary NAG excretion
2.1       Non Renal causes:
                                                               i.      Diabetes  Mellitus
                                                             ii.      Hypertension
                                                            iii.      Metabolic syndrome
                                                           iv.      Obesity
                                                             v.      Preeclampsia
                                                           vi.      Sjogren’s Syndrome
                                                          vii.      Smoking
                                                        viii.      Surgery (Breast, gastric, etc)
                                                           ix.      Coronary artery disease
                                                             x.      Oxidative stress            
                                                           xi.      COPD
                                                          xii.      Active Myocardial Infarction
                                                        xiii.      Leukaemia
                                                        xiv.      Viral Hepatitis
                                                         xv.      Sepsis
                                                        xvi.      Burn
                                                      xvii.      Rheumatoid Arthritis.
                                                     xviii.      Systemic Lupus Erythematous
2.2       Renal causes:
1.      Nephrotic Syndrome
2.      Pyelonephritis
3.      Glomerulonephritis
4.      Renal cell cancer
5.      Renal transplantation


3.1     Acute Myocardial Infarction
Acute myocardial infarction is defined as acute ischemic necrosis of an area of myocardium. It is also defined as myocardial necrosis occurring as a result of a critical imbalance between coronary blood supply and myocardial demand.
In 1999, a case-control study (cases = 69, controls = 135) found that mean NAG levels were significantly (p = 0.0001) higher (10.92 ± 7.5 U/L) in patients diagnosed with acute myocardial infarction when compared with normal healthy individuals (6.8 ± 2.17 U/L).1
The same investigators estimated plasma NAG through Whiting’s method. 2 Similar findings were also reported from two studies. 3, 4 However, the authors did not discuss clearly the underlying biological mechanism of such observations.

3.2     Rheumatoid Arthritis
Rheumatoid arthritis is a chronic symmetrical polyarthritis of unexplained cause. It is a system disorder characterized by chronic inflammatory synovitis mainly affecting peripheral joints.
In a case-control study in Pakistan, Iqbal and colleagues showed that mean urinary NAG levels were significantly higher (p< 0.05) in patients (n=49) with sero-positive Rheumatoid arthritis (4.2 U/g ) when compared with 15 healthy subjects (1.71 U/g ).5
The same authors also showed that in patients with RA when treated with low dose of methotrexate, the urinary NAG levels did not affect renal tubular function.5

3.3     Systemic lupus erythematous (SLE)
SLE is a multisystem connective tissue disease characterized by the presence of numerous autoantibodies, circulating immunologically determined tissue damage.
In 2004, Mark and colleagues  in the UK found that mean NAG levels were significantly higher in patients of Lupus Nephritis when compared with both normal control groups (p = 0.001) and Lupus Non Nephritis group (p = 0.001).6

 Urinary NAG              Normal          Lupus Non           Lupus               
 (log/median)               controls         Nephritis             Nephritis

0.15-1.44         0.88-1.86             1.23-2.64                P = 0.001
            (1.03)               (1.02)                   (1.80)

Mark and colleagues also indicated that two patients of lupus non-nephritis who had taken NSAIDs (Non-Steroidal Anti-inflammatory drugs) had the lowest urinary NAG levels among all the 21 patients of SLE studied. In lupus nephritic patients, 60% of these had elevated urinary NAG levels. The authors concluded that such findings in lupus non-nephritis patients might help to identify lupus nephritis prior to tubular dysfunction.6

3.4     Cancers
In cancer, abnormal cells divide (mitosis) without control. Cancer cells can invade nearby tissues and spread through the blood stream and lymphatic systems to other parts of body (metastasis).Cancer cells also avoid natural cell death (apoptosis).
An animal study on rats in Korea in 2004  examined whether NAG -1 expression was induced in gastric cancer cells treated  with NSAIDs, and also the effect of NAG -1 expression on cell deaths.7
Jang and colleagues observed that NAG -1 expression was strongly induced in SNU 601 cells which lacked endogenous Cox -2, and this was closely related with increased apoptosis and decreased cell viability. 7  The investigators also found NAG -1 expression to be closely related to DR-4 and DR-5 induction, which could provide a mechanistic basis for the apoptotic effect of Cox inhibitors in gastric cancer cells.7
Baek et al showed that NAG – 1 has antitumorigenic and a proapoptotic activity in Hct – 116 colon cancer cells devoid of Cox expression (Cyclooxygenase activity).8 However, it is unclear of any significant pathways for engagement by NAG -1.

In 2004, Kralickova and colleagues studied 26 breast cancer patients to look at renal tubular dysfunction and urinary zinc excretion in breast cancer patients treated with antthrcycline based chemotherapy. 9 They found increased urinary NAG activity in breast cancer patients, who were treated with anthracycline groups and had associated symptoms of hyperzincuria and hypozincemia. However, the authors also showed that urinary NAG levels were associated with a decrease in serum creatinine level, which is consistent with hyperfiltration. Such changes are not related with abnormalities of renal zinc handling or a decrease in serum zinc concentration.9
Luqmani Y et al in1999 in Kuwait discussed in a case-control study that breast cancer patients (n=129) had significantly higher (p=0.002) NAG activity fluctuations within a narrower range (11.6 units /l) when compared with healthy subjects (n=28).10

3.5     Preeclampsia
In 2003, Semezuk–Sikora and colleagues looked at 84 third trimester women in Poland.11 With history of hypertension, they observed the highest urinary NAG levels in preeclampsia women (median -1.520 u/mmol ), while in women with pregnancy induced hypertension, the NAG levels (median -0.874 U/mmol ) differed  significantly from the controls ( median 0.782U/mmol ).However, there was slight positive correlation between NAG and systolic blood pressure (r = 0.225, p< 0.05). Therefore, the authors hypothesized that hypertension in pregnancy might lead to renal tubular damage, and this needs further investigations.11

3.6     Diabetes Mellitus
Diabetes Mellitus (DM) is a syndrome, caused by the lack of or diminish effectiveness of endogenous insulin and is characterized by hyperglycemia and deranged metabolism. It is primarily of two types: type I and II.

3.6.1    In children and adolescents (type I DM):
In 2002, Mungan and colleagues demonstrated that urinary NAG activity was significantly higher in 44 type I Diabetic Mellitus patients (5.6 ± 0.6 U vs. 1.6 ± 0.2 U) when compared to controls.12 However, none of the microalbuminuria-related variables were significantly correlated with urinary NAG activity in this study. Therefore, the authors concluded that urinary NAG activity might not appear to be a useful marker for children and adolescents with type I DM.12
Following Mungans’ study,12 Salem et al found significant correlation between  urinary β-NAG and RBP ( retinol binding protein ) in normoalbuminuric  patients (r = 0.66, p< 0.001 ) as well as between each of the two tubular markers and HbA1c (r = 0.83, p < 0.001; mean  β-NAG = 6.88 vs. 3.76 U/g).13 They argued that markers of tubular damage, including urinary β-NAG and RBP, were excreted in large quantities in Diabetic patients with or with out  microalbuminuria. However, the authors concluded that NAG is a useful marker in type I DM.13

  β- NAG                     Controls        All DM        With Micro-         With Normal
                                                                                albuminuria          albuminuria

   (U/g)                          (n=40)            (n=59)            (n=11)
__________________________________________________________________________________

                                      3.8 ±1.1       7.7 ±3.2         11.16±1.23           6.88 ±299

In 1991, Agardh and others did a case-control study (14), and found that diabetic patients (n=87) had significantly higher level of urinary NAG than the control subjects (p<0.01), but isoenzyme pattern did not differ. 14 They also observed a significant association between metabolic control and total NAG (p<0.01). Their findings also demonstrated that concentrations of urinary NAG were positively correlated with the degree of nephropathy but not with retinopathy.14

3.6.2  Type II Diabetes Mellitus
In 2000, a cross- sectional study done by Hong et al in Singapore (n = 972) found that the level of urinary NAG was higher in type II DM, with complications.15 Therefore, the authors concluded that NAG was an independent predictor of renal complications in type II DM.15
However, the differences reached statistical significance only for albumin and RBP
(microvascular vs. no complication), as the following table shows:15

Nag total                     No                 1/> macro         1/>micro     any one                                                    complication                                               complication      
(nmol/min/g)     
                                                                                                                             Unadjusted                                                           3.14                 3.21                   3.84           4.85
 Adjusted                     3.22                 3.16                   3.80           4.61
Nag-B  
(nmol/min/g)

Unadjusted                   0.27                 0.22                   0.25           0.40
 Adjusted                     0.27                 0.21                   0.25           0.38

There was no observable  difference between hypertensive patients and normotensive patients with regard to NAG –total excretion, and any observable difference for NAG- B was also small.15 Such findings were also reported from several studies.16-19

In 1999, a cross-sectional study by Weitgasser et al showed that urinary NAG activity was significantly (<0.05).elevated at baseline in type II DM when associated with cardiovascular diseases (7.7 ± 1.4 vs. 5.4 ± 0.5 in with/without cardiovascular diseases, respectively).20

Myocardial                 Stroke                           PVD                   No CVD
Infarction

7.0±0.4                        3.5±0.7                         9.1±2.8               5.8±0.7
(10±3.5)                      (4.9±12)                       (7.3±3)               (6.2±1.2)

The above study also provides evidence for determining glomerular and tubular renal function in DM patients with macrovascular complication. 20 However, further study is required for cardiovascular disease complications.

3.7     Hypertension
The British Hypertensive Society defines Hypertension as sustained Diastolic > 100 mm Hg on ≥ 3 reading each week a part and Diastolic > 90 mm Hg over  6 month or if Systolic > 160 mmHg and Diastolic 90- 99 mm Hg.

In 2003, TylickI et al conducted a case-control study in Poland on 25 newly-diagnosed non treated hypertensive patients with out microalbuminuria.21 They found that urinary NAG activity was significantly higher in hypertension (p = 0.04), and was negatively correlated with creatinine clearance (p = 0.034). However, they showed a significant positive correlation of urinary NAG with systolic blood pressure in patients with hypertension. Following a multiple regression analysis, the investigators also showed that NAG activity was significantly influenced by systolic blood pressure and plasma glucose level (p = 0.003 and p = 0.042, respectively) in hypertension patients.
Similar hypothesis in hypertension patients was also generated in subsequent studies, 22, 23 using urinary NAG as a marker for tubular injury. However, they did not find a significant association between any lipid levels and uric acid concentration with urinary NAG activity.

In 2000, Kretowicz et al study in Poland about essential hypertension and NAG found that hypertension in metabolic syndrome might be due to tissue injury. 24 They did a case-control study, 11 were hypertensive and the remaining 14 were healthy subjects. They found a significantly higher urine excretion of NAG (2.75± 1.69 vs.  1.82 ± 1.46 p < 0.05), while a tendency to a significantly higher urine fractional sodium excretion with out a significant difference in albumin excretion. They also found a negative linear correlation between mean arterial pressure and urinary NAG excretion in the group of hypertensive patients, which might reflect the renal ischemia in tubulo-interstitial pathology.24

In 1999, another case-control Polish study looked at the relationship between excretion of the markers of tubular damage (NAG in particular) and other parameters of essential hypertension.25 They showed a statistically significant higher BMI (p < 0.007), NAG (p < 0.02), and total cholesterol (p < 0.01), as well as a positive correlation of NAG excretion with hypertension. The authors, therefore, hypothesized that tubular injury at an early stage of renal damage in patients with essential hypertension could be a part of metabolic syndrome X.25

3.8     Coronary Artery Disease
Coronary artery disease (CAD) is characterized by atherosclerosis of the coronary arteries causing angina pectoris and myocardial infarction.

In 1999, Inoue et al on coronary artery disease and NAG showed that serum NAG activity increased in multivessel coronary disease as well as in patients with no stenotic lesions or with single vessel coronary artery disease.26 However, clinical serum NAG activity is yet to be defined. Serum NAG activity has also been recently reported to be elevated in Hypertension, DM, and Renal disease. In acute myocardial infarction, elevated NAG activity in patients with multi-vessel disease has been shown not to be derived from the breakdown of myocardial cells.26

Nonetheless, serum NAG activity in patients with coronary artery disease and cerebrovascular disease was shown to be 30٪ higher than that in healthy control subjects. 26   In this study, limited patients who have had coronary artery disease were enrolled, but not having atherosclerotic cerebrovasular disease, or peripheral vascular disease. The study also included hypertension, single coronary artery disease and multivessel coronary artery disease groups, and showed that there was no significant difference in serum NAG activity between males and females (8.7± 2.3 vs. 8.1 ± 2.8 U/l).The serum NAG activity was  9.2 ± 2.3 U/l in the multi-vessel disease group, which  was significantly (p<0.01)higher than (7.8 ± 1.8 U/l) in the no stenotic lesion group, as well as (8.2 ± 2.2 U/l; p < 0.05) in the single–vessel disease group. Therefore, the authors suggested that hyperinsulinemia or insulin resistance might be independent risk factors for coronary artery disease and that serum NAG activity might contribute to the severity of coronary artery disease associated with insulin resistance.26

3.9     Renal Causes
3.9.1  Primary nephritic children
It is post-streptococcal glomerulonephritis, usually a child will have suffered a streptocococcal infection 1-3 weeks back before the onset of acute nephritis syndrome.

In 1996, a study in Turkey on children having Nephrotic Syndrome, with and without steroid– resistance, was compared with healthy children.27 They found a significantly higher level of NAG in the nephrotic groups compared to the controls ( p < 0 0.0001), as well as in steroid – sensitive patients the level of NAG was significantly higher than those in remission (p < 0.0001). Finally, they also found positive correlation between proteinuria and urinary NAG excretion in nephritic patients when compared with controls (r = 0.069, p < 0.001 and r = 0.39, p < 0.001, respectively). The authors argued that massive glomerulo-proteinuria might cause urinary NAG excretion in primary renal disease.27

In 1993, a study in the UK on 65 children with steroid sensitive multirelapsing nephrotic syndrome, 28 were on cyclosporine A9 CyA therapy, 22 on prednisolone, and 15  were off treatment were compared with 32 ) normal children.28 They found geometric mean urinary NAG  to be significantly higher in nephritics on CyA therapy (26.5 ± 4.0) and on P (37.0 ± 7.9) as well as in those off treatment (16.3 ± 3.1) when compared with normal children (9.3 ± 3.4). Therefore, the authors suggested that increased NAG in urine might indicate active nephritic syndrome rather than due to drug therapy alone.28

3.9.2  Primary Glomerulonephritis
Primary glomerulonephritis is a group of diseases in which the disease affects the glomerulus and is often inflammatory in nature. It may be primary when major problem starts in the glomerulus or secondary when involvement is part of systemic disease.

In 2002, Bazzi  et al in Italy looked at patients with primary glomerulonephritis, with idiopathic membranous nephropathy (IMN), with primary focal segmental glomerulosclerosis (FSGS) and patients with minimal change disease (MCD).29 They limited their statistical analysis to (n = 67) patients with nephritic syndrome alone and observed that NAG was significantly dependent on IgG excretion (p = 0.0004), 24 hrs proteinuria (p = 0.0067) and FEalpha (1)-m (p = 0.0032)( R(2)=0.63).

The same study found that NAG excretion predicted remission in 86 vs. 27٪ of IMN patients (p= 0.0002) and 77 vs. 14 ٪ of FSGS patients (p =0.005).29 Using Cox model in IMN patients only NAG excretion (p = 0.01, r= 5.8), but not 24-h proteinuria predicted progression to CRF. All MCD patients had NAG excretion values were below the chosen cut – off, and 90 ٪ of them developed remission. Response to immunosuppressive therapy was significantly different in patients with NAG excretion values below or above the cut- offs. Finally, the authors concluded that NAG was a reliable marker of the tubulo-toxicity of proteinuria in the early stage of IMN, and it had a predictive value on functional outcome, as well as on response to therapy.29

3.9.3  Acute pyelonephritis
Acute pyelonephritis is a kidney parenchymal infection that occurs most often as a resulting of ascending infection from the bladder.

In 2004, Polish researcher Zoch-Zwierz and colleagues found that NAG activity was higher in children with pyelonephritis (r = 0.9355; p = 0.00001), with a significant correlation with acute pyelonephritis.30

3.9.4  Chronic Renal insufficiency
In 2003, Tassi et al did a study in Italy where they looked at the correlation between chronic renal insufficiency patients and 24-hr urinary NAG levels, and found a significant positive correlation (r = 0.431; p = 0.017).31 The authors suggested that total effective daily excretion of urinary NAG could have practical importance not only for early recognition or renal co-involvement but also that it could be repeated in serial measurements to monitor. Example include, therapies aimed at stopping the progression of renal damage. Finally, the authors concluded stating that sampling 24 hr urine and monitoring total enzyme eliminated in urine over 24hrs could be a potential investigation for chronic renal insufficiency patients.31

3.9.5  Renal failure
Renal failure is defined as the inability of the kidneys to excrete wastes and to help maintain the electrolyte balance.

In 1997, a Polish study on 63 renal failure patients found that 95.2% (n=60) of the patients with chronic renal failure had abnormal NAG values (> 70 nmol/mg).32 The authors demonstrated significant differences of NAG values between  patients with massive proteinuria (> 1.5 g /24 h), moderate proteinuria and those without 24h proteinuria or non-significant proteinuria (423.5±286.3 vs. 414.4 ± 334.8 vs. 453.0 ± 451.3 nmol/mg, respectively).However, there was no significant difference in patients with NAG values above and below 280 nmol/mg. The authors, therefore, suggested that measurement of NAG secretion might be helpful to delineate the disease process in renal failure patients.32

4.       Biological Mechanism?
             The above discussion suggests that the underlying biological mechanism between various disease conditions studied (both renal and non-renal) and the increased NAG activity is still unclear. Some plausible mechanisms have been postulated. The most consistent underlying mechanism suggested is related to oxidative stress.  For example, in type I diabetes mellitus patients the increased serum NAG activity is observed before the development of retinopathy.33 Therefore, NAG was suggested to be an early marker of vascular changes in diabetes. Also, significant positive correlation exists between NAG activities and malondialdehyde (MDA) concentration in type I DM supporting that oxidative stress may influence NAG activities. 33 A decrease in NAG activity following anti-oxidant treatment (alpha-tocopherol) may further support the role of oxidative stress in modulation of NAG activities. 33 Such positive relationships are also consistent in before and after experiment. 33 All together, it is probable to conclude that oxidative stress not only influences endothelial dysfunction, but also participates in the modulation of enzyme activities. The endothelial cells are one of the sources of NAG, mainly serum NAG. In addition, greater oxidative stress may be present in obese persons and therefore more advanced endothelial activation would be expressed. Secondly, NAG is also postulated to have free radical-scavenging and apoptosis-inducing property against certain types of cancers.34

5.       Summary and Conclusion
             NAG is excreted from lysosomes, and its increased activity reflects organ system damage. Urinary NAG primarily present in proximal renal tubules contributes to increase NAG activities in all the disease conditions studied (both renal and non-renal). Chronic disorders, such as hypertension, diabetes mellitus, acute myocardial infarction and cancers are the main non-renal conditions where increased NAG activities are observed. The underlying biological mechanism of such observations is still unclear. Nevertheless, postulations such as oxidative stress leading to endothelial dysfunction, as well as apoptosis-inducing property have been suggested. Therefore, it is clearly important that further explorations are necessary to establish the causal pathway. Despite such limitation, NAG can be a useful marker of tubular damage involving both renal and non-renal disease states.

References:

1. Iqbal MP, Kazmi KA, Jafri HR, Mehboobali N. N-Acetyl-β-D-glucosaminidase in acute myocardial infarction. Exp Mol Med 2003; 35(4): 275-278.

2. Whiting PH, Ross IS, Borthwisk L. Serum and N-acetyle-β-D- glucosaminidase in diabetics on diagnosis and subsequent treatment and stable insulin dependent diabetics. Clinica Chimica Acta 1979; 92: 459-463.

3. Welman E, Colbeck JF, Selwyn AP, Fox KM, Orr I. Plasma lysosomal enzyme activity in acute myocardial infarction and effects of drug . Adv Myocardiol 1980; 2:359-69.

4. Inoue T, Matsunage R, Morooka S. Serum N-actyl –beta-D- glucosaminidase activity increases in associated with insulin resistance in patients with coronary artery disease. Atherosclerosis 2000; 149:17-22.

5. Iqbal MP, Ali AA, Waqar MA, Mehboobali N.Urinary N- acetyl- beta- D- glucosaminidase in Rheumatoid Arthritis. Exp Mol Med 1998; 30(3): 165-9.

6. Marks SD, Shah V, Pilkington C, Woo P, Dillon MJ. Renal tubular dysfunction in children with system lupus erythematosus. Pediatr Nephrol 2005; 20(2):141-8.

7. Jang TJ, Kang HJ, Kim JR, Yang CH. Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulphide induced gastric cancer cell apoptosis. Carcinogenesis 2004; 25(10):1853-1858.

8. Baek SJ, Kim KS, Nixon JB, Wilson LG, ELing TE.Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has propoptotic and antitumorigenic activites. Mol Pharmacol 2001; 59: 901-908.

9. Kralickova P, Melichar B, Malir F, Roubal T. Renal tubular dysfunction and urinary zinc excretion in breast cancer patients treated with anthracycline-based combination chemotherapy. J Exp Clin Cancer Res 2004; 23(4):579-84.

10. Luqmani Y, Temmim L, Memon A, et al. Measurement of serum N-acetyl beta glucosaminidase activity in patients with breast cancer. Acta Oncol 1999; 38(5):649-53.

11. Semezuk-Sikora A, Sikora P, Biadun U, Semezuk M. Urinary N-actyl-beta-D-glucosaminidase (NAG) excretion in women with pregnancy complicated with hypertension. Glinekol Pol 2003; 74(10):1267-75.

12. Mungan B,Yuksel M, Bakman A, Topaloglu K, Ozer G. Urinary N-acetyl-beta-D-glucosaminidase activity in Type I Diabetes Mellitus. Indian Pediatr 2003; 40:410-414.

13. Salem MAK, E1-Habashy SA, Saeid OM, E1-Tawil MMK,Tawfik PH. Urinary excretion of n-acetyl-β-D-glucosaminidase and retinol binding protein as alternative indicators of nephropathy in patients with type1 Diabetes Mellitus. Pediatr Diabetes 2002; 3:37-41.

14. Agardh CD, Agardh E, Isaksson A, Hultberg B. Associtation between Urinary N-Acetyl-β-Glucosaminidase and Its Isoenzyme Patterns and Microangiopathy in Type I Diabetes Mellitus. Clinical Chem 1999; 37(10):1696-1699.

15. Hong CY, Chia KS, Ling SL. Urinary protein excretion in
Type 2 diabetes with complications.
J Diabetes Complications 2000; 14: 259-265.

16. Marshell SM, Alberti KGMM. Comparison of the prevalence and associated features of abnormal albumin excretion in insulin-dependent and type 2 diabetes. Q J Med 1988; 70:60-71.

17. Mattock MB, Keen H, Viberti GC, et al. Coronary heart disease and urinary albumin excretion rate in type 2 (type 2) diabetic patients. Diabetologica 1988; 31: 82-87.

18. Stiegler H, Standl E, Schulz K, Roth R, Lehmacher W. Morbidity,
Mortality and albuminuria in type 2 diabetic patients; a three year prospective study of a random cohort in general practice
. Diabetes Med 1992; 9: 646-653.

19. Araki S, Kikkawa R, Haneda M, et al. Microalbuminuria cannot predict cardiovascular death in Japanese subject with type 2 diabetes mellitus. J Diabetes Complication 1995; 9: 323-325.

20. Weltgasser R, Gappmayer B, Schnoell F, Karting I. Prospective evaluation of Urinary N-actyl-β-D-Glucosaminidase with respect to Macrovascular Disease in Elderly Type 2 Diabetic patients. Diabetes Care 1999; 22:1882-1886.

21. TylickI L, Manitius J, Lysiak-Szydlowska W, Ruthowski B. Tubular injury : the first symptom of hypertensive kidney involvement? Med Sci Monit 2003; 9(4):CR187-193.

22. Rutkowski B, Tylicki L, Manitius J, Lysiak-Szydlowska W. Hypertensive nephropathy- an increasing clinical problem. Miner Electrolyte Metab 1999;25:
65-68.

23. Price RG. Urinary enzymes, nephrotoxicity and renal disease. Toxicol 1982; 23:
99-134.

24. Kretowicz M, Ukleja-Adamowicz M, Strozecki P, et al. Does any relationship exist between metabolic disturbances and some markers of renal damage in patients with untreated essential hypertension? Pol Arch Med Wewn 2000; 104(3): 563-7.

25. Ruthowski B,Tylicki L, Manitius J, Lysiak-Szydlowska W. Hypertensive nephropathy- an increasing clinical problem. Miner Electrolyte Metab 1999; 25(1-2):65-8.

26. Inoue T, Matsunaga R, Morooka S, Uehara Y. Serum N-acetyl-β-D-glucosaminidase activity increases in association with insulin resistance in patients with coronary artery disease. Atherosclerosis 2000; 149: 117-122.

27. Caliskan S, Hacibekiroglu M, Sever L, Ozbay G, Arisoy N. Urinary N-actyle-beta-D-glucosaminidase and beta 2- microglobulin excretion in primary nephritic children. Nephron 1996; 74(2):401-4.

28. Piqueras AI, Shah V, Hulton SA, Barratt TM, Dillon MJ. Tubular proteinuria in steroid sensitive multi-replapsing nephritic syndrome. Clin Nephrol 1993; 40(10):26-30.

29. Bazzi C, Petrini C, Rizza V, et al. Urinary N-actyl-beta-D-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002; 17(11);1890-6.

30. Zock-Zwier W, Kepka A, Tomaszewska B, et al. Assessment of fructose-1,6-biphoshatase in urine of children with acute pyelonephritis. Pol Merkuriusz Lek 2004; 16(91): 56-9.

31. Tassi C, Mancuso F, Feligioni L, Marangi M, Capodicasa E. Expression modes of urinary n-acetyl-β-D-glucominidase in patients with chronic renal insufficiency. Clinica Chimica Acta 2004; 346: 129-133.

32. Szechinski J, Wiland P. Renal proximal dysfunction based on activity of n-acetyl-beta-d-glucosaminidase in urine of patients with kidney failure. Pol Arch Med Wewn 1997; 98(12): 536-41.

33. Skrha J, Hilgertova J. Relationship of serum N-acetyl-beta-glucosaminidase activity to oxidative stress in diabetes mellitus. Clinica Chimica Acta 1999; 282: 167-174.

34. Poulose SM, Harris FD, Patil BS. Citrus limonoids induce apoptosis in human neuroblastoma cells and have radical scavenging activity. J Nutr 2005; 135(4): 870-877.

Monday, September 21, 2009

METABOLIC SYNDROME

Review Article
(Syndrome X/ Insulin Resistance Syndrome)

Dr.ISHRAT ALI SIDDIQUI . PROF.J FEELY.
TRINITY COLLEGE RESEARCH CENTRE
PHARMACOLOGY AND THEAPEUTIC
ST ;JAMES HOSPITAL ,
DUBLIN 8 , IRELAND

Definition: Metabolic Syndrome is a cluster of disorders of the body metabolism. Its characteristic including, glucose intolerance hyperinsulinemia hypertriglycermia hypertensin reduced concentration of HDL-cholesterol, and central Obesity are the predominant components.1

This is a review study on metabolic syndrome (MS), with the following objectives:

Study objectives:
1-  To assess the utility of clinical definitions of metabolic syndrome (MS)
2 - To identify individuals with increased cardiovascular risk.
3 - To assess the association between MS and arterial stiffness

1. Utility of clinical definitions of MS

For MS definition, the two most commonly used criteria: Are the ATP III (ADULT TREATMENT PANEL III), and the WHO (WORLD HEALTH ORGANIZATION) criteria. 1 At the outset, a brief background into MS (both epidemiological and clinico-pathological profile) is given.

ATP III (Adult Treatment Panel III):
The ATP IIII criterion describes MS, if any three of the following five criteria is present: 3
1 - Hypertension
2 - Excessive Waist Circumference.
3 - High fasting glucose
4 - Hypertriglyceridemia
5 - Low HDL

WHO clinical criteria:
Insulin resistance is identified by 1 of the following criteria:,4
1- Type II D.M
2 - Impaired fasting glucose
3 - Impaired Glucose tolerance.
4 - For those with normal fasting glucose levels (< 110 mg/dl). For back ground population under investigation under hyperinsulinemic, euglycemic conditions.

Plus any 2 of the following criteria:
1 - Antihypertensive medication and / or high blood pressure
(=>140 mmHg systolic or =>90mmHg diastolic)
2 - Plasma triglycerides (=>150mg/dl/=>1.7mmol/l)
3 - HDL Cholesterol (< 35 mg/dl / < 0.9 mmol/l in Men
Or < 39 mg / dl /1.0 mmol/l in Women)
4 - BMI (> 30 Kg /msquare and / or Waist hip ratio > 0.9 in Men or > 0.85 in Women)
5 - Urinary albumin excretion rate (=> 20 μg / min) or albumin: creatinine ratio (=> 30 mg /g/)
0r
WHO.
1 - Diabetes.IFG, or HOMA – IR
2 - Blood pressure (=> 160 systolic or=> 90 diastolic mmHg).
3 - Hypertriglyceridemia (=> 150 mg/dl )
4 - Low HDL ( Men < 35: Women < 39 mg/dl )
5 - Obesity (waist to hip ratio: Men >0.9, Women >0.85 )5

 NCEP ATP III clinical criteria for MS:

Risk factors, such as:

1 - Abdominal obesity (waist circumference:
      Men > 102 cm (> 40 inches           Women > 88 cm (> 35 inches)

2 - Triglycerides (=> 150 mg /dl/=>1.7 mmol/l)
3 - HDL Cholesterol;
      Men < 40 mg /dl (< 1.0 mmol/l)     Women < 50 mg/dl (< 1.3mmol/l)

4 - Blood pressure (=> 130 mmHg systolic or => 85 mmHg diastolic)
5 - Fasting Glucose (=> 110 mg/dl /=>6.1 mmol/l )

Incidence of MS:
In America, the incidence of MS is increasing over the past ten years, and has reached 61%. One in four adults below the age of forty years has MS.6

Definition of MS: 7
1 - This is the association of insulin resistance in tissues, with hyperinsulinaemia (fasting insulin > 89.4 pmol/L)
2 - Abdominal obesity or central obesity; Waist measure,
      Men = 40inches or more (102cm)      Women=35inches or more (88 cm).

3 - Hypertension;
     Systolic BP = 135 mm Hg
     Diastolic BP = 85 mm Hg.
4 - Hyperglycaemia or Fasting Glucose Level = 110 mg/dl or more.
5 - Increase Plasma Triglyceride Level = 150 mg/dl or more
6 - Decrease HDL OR Low HDL [ good ] Cholesterol below;
     Men = 40 mg/ dl.                              Women = 50 mg/ dl.


It has also been argued that MS is not a disease, but a cluster of disorders of our body metabolism. 8 There are five clusters, and the presence of any three will qualify a patient to have MS. These include:
1- High Blood Pressure
2- High Insulin Level
3 -Excessive Body Weight
4-Abnormal Cholesterol Level
5-Low HDL Level and High HDL

Causes of MS:
The exact cause of MS is not known,8 but few factors are associated with MS. They are:9
1 - Obesity
2 - Hypertension.
3 - Pregnancy.
4 - Asian Origin
5 - Acute and Chronic Renal Failure.
6 - Acromegaly
7 - NIDDM
8 - Sympathetic tone Increase
9 - Cystic fibrosis
10-Poly Cystic Ovaries.
11-Ataxia telangiectasia.

Risk factors for MS:
A few risk factors associated with MS have been identified. They are:

Age:
Less than 10% of the patients in their 20s are diagnosed with MS, while 40% are in their 60s.10

Race:
MS is more common in blacks and in Mexican – Americans than among Caucasians.
Also, black women are affected more relative to black men, while white men are relatively more affected.11

Obesity:
1 - Genetically.
2 - Excessive taking fatty meal.
3 - Less Physical work.
4 - Because of Disease.
5 - Excessive Calorie in take 12

History of Diabetes Mellitus (DM):

MS is more common in the following categories of patients:
1 - Family history of type II DM
2 - History of DM during pregnancy (gestational DM)

Others:
1 - Hypertension
2 - Cardiovascular Disease.
3 - PCO.(Polycystic ovary syndrome)

PATHOGENESIS OF MS:
The most of the body glucose is derived from liver and then kidney produce less glucose.13
And this glucose production is used in the brain and all body tissues in the shape of insulin.
Glucocorticoids are also involved in metabolic inflammatory, cardiovascular and in behavioural process. The cause of action in MS has not been appreciated, but clinical findings suggest that glucocorticoids may play an important role.14
Following glucose ingestion, plasma glucose concentration increases, which stimulate Insulin release and may give rise to Hyper-insulinemia and Hyperglycemia.15
Genes may also play role in MS, because MS is reported to be clustered in a family. 16
When insulin hormone is excreted from pancreas, the pancreas loses its ability to absorb glucose from blood. This blood glucose uses body for energy, and because of excessive dietary intake pancreas releases a high level of insulin in the blood stream. However, loss of insulin production may be genetic or secondary to high fat level with fatty deposits in the pancreas.17

2. Studies on the cardiovascular risk pattern for MS

The STRONG HEART STUDY 18
The strong heart study done by Chinali and colleagues in North Dakota in American Indians (USA) between July 1989 and January 1992 used the ATP III criteria .Their main conclusions were .In Women MS is ( p< 0.001 ) more found with similar aged compare with those with out the MS.
                            After controlling for confounders, the participants with MS had great dimessio, mass and relative wall thickness, and left atrial diameter ( all p < 0.05 ),mid wall shortening ( p < 0.001 ) and mitral E/A ratio ( p< 0.05 ),then participants who did not have the MS.
                          After different experiment process, high blood pressure ( BP ) and abdominal obesity were the only components of the MS associated with increased LV diameter, only high BP was associated with increased LVmass and prevalence of LV hyper trop( both p < 0.001 ).

The Third National and Nutrition Examination Survey 19- 20
This study was done in Boston (USA) in 2004.
The investigators also used ATP III Criteria to determine the prevalence of MS in the American adolescents (12-19 year-olds) across different ethnic groups. They observed variations across ethnic groups. For example, low HDL and Hypertriglyceridemia were more common in the adult non-Hispanic whites, while they are less common in the non-Hispanic blacks. The investigators also noticed that the incidence of MS was 8 % to 12 % in the non-obese adults, while it is 34 % to 41 % in the obese adults. However, the prevalence of MS was comparable for both boys and girls, as well as across older and younger adolescents.

The Health ABC Study 21
The health ABC Study done by Paul Holvoet et al in Belgium between March 1997 and 1998 looked at the elderly People in the Health, Aging, and Body Composition Cohort (ABC).They used ATP III Criteria, and showed that MS was associated with higher levels of oxLDL due to a higher fraction of oxLDL, but not because of higher cholesterol level. The oxLDL was not the lone predictor of total CHD risk, but high oxLDL showed a greater predisposition to myocardial infarction, suggesting atherothrombotic role.

The Arab American Study 22
The Arab American study done in USA in June 2003 investigated into the prevalence of the MS among Arab Americans. They used both the criteria: ATP III and WHO for the diagnosis of prevalence of MS.
                              According to ATP III ,this study showed that the rates were similar for men and women aged 20 – 40 years, but higher for women aged >/=50years. According to WHO, this study showed that the rate is higher for men then women aged 20- 49 years, but similar for age >/=50years.
The prevalence of MS based on both this criteria was 23 % (ATP III) and 28 % (WHO). The study also indicated that the prevalence of MS increased with age and BMI. The WHO criteria analysis also showed that glucose intolerance or glucose resistance, as well as high blood pressure were the most common abnormalities in both sexes. However, the ATP III criteria-based analysis showed that low HDL cholesterol was higher in both the sexes. This low HDL is danger for blood vessel, because of the potential for atheroma formation, thereby narrowing and causing arterial stiffness. Therefore, this study suggested that low HDL cholesterol and triglyceride are powerful predictors of insulin resistance than obesity, elevated blood pressure or FPG. However, in the presence of obesity, the risk of coronary heart disease is greatly increased.

The ARIC Study 23

The ARIC study was done in North Carolina (USA) between 1987 and 1989 to determine the prevalence of Coronary Heart Disease and Carotid Arterial thickening. The investigators used ATP III criteria, and studied different racial and age groups. The main findings of this ARIC study were that women alone with MS had a significant association with increasing low density lipoprotein cholesterol. CHD prevalence was 7.4 % compared to 3.6 % prevalence in the comparison subjects ( p < 0.0001 ). In other words, MS patients were 2 times as more likely to have CHD as those without MS. The study also indicated that the average intimal–medial wall thickness of carotid arteries was greater among the MS patients versus those with out MS.

The Greenland Study 24
The prevalence of the MS among the Inuit in Greenland.A Comparison b/w two proposed definition .Study by M.J.Jorgensen et all in Denmark in b/w 1999 and 2001.
They used both the criteria, WHO, ATP III. This study compared WHO Syndrome men with NCEP Syndrome, and found higher mean values of waist circumference, BMI and triglycerides and lower mean values of high – density lipoprotein ( HDL ) Cholesterol.among women,triglycerides were higher NCEP Syndrome.
The study also indicated increased prevalence of D.M, because of impaired tolerance and obesity, together with higher physical inactivity levels. All this may have caused increased insulin resistance. According to WHO definition, 37.9 % did not have MS, while according to NCEP Syndrome definition 28.5 % had MS.

The investigators showed that MS is increased with age in men in both the syndrome and women were affected only when they became older. Men with WHO Syndrome had lower waist circumference and triglyceride levels but HDL cholesterol was higher in women. However, the level of risk is same except from HDL cholesterol, which was higher according to WHO Syndrome.

Glucose abnormality is also higher in women with WHO Syndrome but in NCEP syndrome 72% of women with IGT and 43% of women with Diabetes were not classified as glucose intolerance. Obesity was much higher with WHO than NCEP. Hypertension was high according to NCEP, because of lower thresholds. The study indicated that prevalence of these two syndromes is equal, while abdominal fat seems to be a greater risk factor than obesity. Blood pressure was higher according to WHO. Microalbuminuria was associated with endothelial dysfunction and with increased risk for CVD, both in diabetic or non-diabetic patients. NCEP Syndrome showed increased IHD mortality, while WHO Syndrome showed increased CVD mortality.

This study is done by Marchesini G et al in 1999 in Bologna, Italy. The investigators employed both WHO and ATP III criteria for the definition of the Metabolic Syndrome in patients with Type 2 diabetes. They found that according to WHO criteria microalbumina has the highest specificity (99 %), while visceral obesity has the highest sensitivity (93 %) for MS.

ATP III criteria showed that hypertension was the most sensitive criterion and low HDL-Cholesterol the most specific (95 %). Positive waist circumference and low HDL Cholesterol were both associated with CHD. Based on the WHO criteria, waist circumference is identified in large proportion of males, while based on ATP III criteria visceral adiposity is more common in females.25

3. METABOLIC SYNDROME CAUSE ARTERIAL STIFFNESS
The mechanisms of development of vascular stiffness is largely unknown. 28
In Metabolic Syndrome, mainly two risk factors are important contributors to the development of atherosclerosis. These are High Density Lipoproteins (HDLs) and Low Density Lipoprotein (LDLs).
            The formation of an atherosclerotic plaque is some form of damage to arterial wall, and this damages the endothelial cells of the tunica intima. Other contributing risk factors are: smoking, poor diet (high saturated fatty intake such as cholesterol), stress, lifestyle and social factors.26
           Schiffrin has shown that arterial stiffness is increased with advance age and other CV risk factors may role in arterial stiffness, such as Hypertension ,MS,Diabetes,Obesity, Hypercholesterolemia and C-reactive protein.27
Arterial Stiffness is related with Insulin resistance in Non Diebetic Hypertensive Older Adult is done by Sendstock DM,et all in university of Michigan.
They recruited 60 to 80 year age ,and measuring pulse pressure and carotid – femoral pulse wave velocity to find out arterial stiffness ,they say that PWVand PP were negatively correlated with SI,and after multiple regression analysis .PWV and PP remained independtly correlated with SI .( P< 0.005 ).28

TECHNIQUE FOR ARTERIAL STIFFNESS MEASUREMENT
Metabolic Syndrome can be diagnosed with invariable investigation is done by tap measure and a few simple blood test6,and also for to find out the cause of arterial stiffness, we take pulse pressure and carotid – femoral pulse wave velocity and different BP reading ,systolic and diastolic with the help of sphygmomanometer.27
               In supine position connect EKG lead and record heart rhythm continuously. Pulse pressures (PP) was calculated by subtracting these measurements. We marked mid point of manubrium to locate maximal impulse of the right common carotid and right common femoral artieries pulses. To approximate the length of the descending aorta, the distance from the midpoint of the manubrium maximal pulse of the right carotid artery was subtracted from the distance from the midpoint of the manubrium to the maximal pulse of the right femoral artery ‘1 aorta (mm)’.A hand –held high-fidelity tometer (SPC-301,Millar instruments, Houston.TX ) placed over the maximal impulse of the carotid artery to achieve a pressure wave contour with a consistent baseline, contour, and amplitude. A twenty – second time span of these carotid pulse contours were recorded ( At Cor version 7.0 ).The average time ‘t C ( msec )’between each R-wave on the EKG and the food of the corresponding carotid pressure waveform was calculated. Similarly, the tonometer was placed over the maximal impulse of the right common femoral artery to calculate ‘tf ( msec )’.PWV ( m / sec) was then calculated by the equation PWV =1 aorta / ( tf-tC).
A measurement was excluded if the pressure contour was of poor quality or if a significant difference (>15%) in the heart rate was found between the carotid and femoral measurements.28

References

1. IMJ November / December 2004 Volume 97 Number 10 .www.imj.ie
2. The Claveland ClinicHealth Information Center;
    http//www.clavelandclinic.org/health-info/does/300/3057/aspp?index
    10783, 18.02.05.
3. Sarah D, de Ferranti, KG, David SL, Ellis JN. Prevalence of the metabolic
    syndrome in American Adolescents). Finding from the third National Health
    and Nutrition examination Survey. Circulation 2004; 110: 2494-2497.
4. Derived from WHO
    www.theses.ulaval.ca/2004/222151/ch01.html,22/02/05.
5. Jaber LAB, Hammad A, Zhu Q, Hermen WH. The prevalence of the
    Metabolic Syndrome among Arab Americans. Care 2004; 27(1):234- 8.
6. MayoClinic Medical Service,Heart Center,March 09,2004.
7. The Pritikin Longevity Center & Spa Welcome You. February 2005.
8. Claveland Clinic.org health / health.info / docs / 3000 / 3057 asp ?index =
    10783 page 1 and 3, 18/02/05.
9. Oxford Hand Book Of Clinical Medicine, page no = 567,fourth edition.
10. MayoClinic.com-Metabolic Syndrome. March 09,2004.31/01/2005.
11. Statistical fact sheet Risk factors (American Heart Association)
12. The Pritikin Longevity Center & Spa Welcomes You.
      http//pritikin.com/eperspective/janfeb05/metabolicMess.stml?OVRAW= metabolic%..18/02/05.
13. Ralph A.Defronzo.(Medical Clinics of North America).
      Doi:10.1016/j.mena 2004.04.013.
14. Minghan Wang, ( Role of Glucocorticoide in M.S ),
      Received Nov=18,2004.acept2005.
15. Medical Clinics of North American. Med clin Nam 88 (2004)787-835.
16. http//www.theses.ulaval.ca/2004/22151/chol.html.22/02/05
17. http//www.Clavelandclinic.org/health/health–info/docs/3000/3057;asp?index=10783=18/02/05.
18. Marcello C, Devereux RB, Howard BV, et al. Comparison of cardiac structure and function in
      American Indians with and with out the Metabolic Syndrome,
      THE STRONG HEART STUDY.Am J Cardiol 2004; 93(1): 40.
19. Sarah D, de Ferranti, Kimberlee G, et al. Prevention of the Metabolic
      Syndrome in American adolescents: Findings from the Third National Health
      and Nutrition Examination Survey. Preventive Cardiology 2004; 110: 2494-2497.
20. Meigs JB, Wilson PW, Nathan DM, et al. Prevalence of the Metabolic
      Syndrome in the Sa Antonio Heart and Framingham offspring studies.
      Diabetes 2003; 52 (8): 2160-7.
21. Paul H, Stephen BK, Russell PT, et al. The Metabolic Syndrome, circulating
      Oxidized LDL,and risk of Myocardial Infarction in well functioning Elderly
      People in the Health, Aging, and Body composition Cohort.
      Diabetes 2004; 53:
22 Jaber LA, Brown MD, Hammad A, Zhu Q, Herman WH. The prevalence of
     the Metabolic Syndrome among Arab Americans. Care 2004; 27 (1): 234-8.
23. McNeill AM, Rosamond WD, Girman CJ, et al. Prevalence of Coronary Heart
      Disease and carotid \rterial thickening in patients with the Metabolic
      Syndrome (The ARIC Study).Am J Cardiol 2004; 94:1249-1254.
24. JØrgensen ME, Bjerregaard P, Gyntelberg F, Borch–Johnsen K. Prevalence of
      the Metabolic Syndrome among the Inuit in Greenland .A comparison between
      two proposed definitions. Diabetes 2004; 21: 1237-42.
25. Marchesini G, Forlani G, Cerrelli F, et al. WHO and ATP III proposals for the
      definition of the Metabolic Syndrome in patients with Type 2 Diabet
      Med.2004; 21 (4): 383 – 7.
26. Douglas BM, Glasgow U.K. In: Principles of Physiology, 1996.
27. Ernesto LS. Vascular stiffening and arterial compliance: Implications for
      systolic blood pressure. Am J Hypertension 2004; 17(12) Supplement 1, S39 - S48.
28. Sengstock DM, Vaitkevicius PV, Supiano MA. Arterial stiffness is related to
      insulin resistance in Non Diabetic Hypertensive Older Adults. J Clin
      Endocrinol Metab 2005; Feb 22 (epub).
                                                                                             COPYRIGHT 2009